Chemotherapy for prostate cancer
Chemotherapy uses anticancer (cytotoxic) drugs to destroy cancer cells. It is sometimes used to treat prostate cancer. Your healthcare team will consider your personal needs to plan the drugs, doses and schedules of chemotherapy. You may also receive other treatments.
Chemotherapy is given to help you live longer and try to improve your quality of life. You may have chemotherapy:
- along with hormone therapy to treat prostate cancer that has spread to other parts of the body (called metastatic castration-sensitive prostate cancer) when you are first diagnosed
- to treat prostate cancer that stops responding to hormone therapy (called castration-resistant prostate cancer)
- to relieve pain or control the symptoms of metastatic prostate cancer (called palliative care)
Chemotherapy is given into a vein (called an infusion) and is a form of systemic therapy. This means that the drugs travel through the bloodstream to reach and destroy cancer cells all over the body, including those that may have broken away from the primary tumour in the prostate.
Chemotherapy is given in cycles. Each period of treatment is followed by a rest period to give your body time to recover. A cycle is often 3 weeks long, with 1 infusion every 3 weeks.
Chemotherapy drugs used for prostate cancer @(Model.HeadingTag)>
Chemotherapy drugs used to treat prostate cancer are:
- docetaxel combined with darolutamide (Nubeqa)
- cabazitaxel (Jevtana)
Your hormone injection must be continued while you receive your chemotherapy.
Side effects @(Model.HeadingTag)>
Side effects can happen with any type of treatment for prostate cancer, but everyone's experience is different. Some people have many side effects. Other people have few or none at all.
Chemotherapy may cause side effects because it can damage healthy cells as it kills cancer cells. If you develop side effects, they can happen any time during, immediately after or a few days or weeks after chemotherapy. Sometimes late side effects develop months or years after chemotherapy. Most side effects go away on their own or can be treated, but some side effects may last a long time or become permanent.
Side effects of chemotherapy will depend mainly on the type of drug, the dose, how it's given and your overall health. Some common side effects of chemotherapy drugs used for prostate cancer are:
- nausea and vomiting
- low blood cell counts (called bone marrow suppression)
- hair loss
- sore mouth and throat
- loss of appetite
Tell your healthcare team if you have these side effects or others you think might be from chemotherapy. The sooner you tell them of any problems, the sooner they can suggest ways to help you deal with them.
Peter Chung, MBChB, FRCPC
Krista Noonan, MD, FRCPC
American Cancer Society. Treating Prostate Cancer. 2019: https://www.cancer.org/.
American Society of Clinical Oncology. Prostate Cancer. 2020: https://www.cancer.net/.
Tracy, CR. Prostate Cancer. eMedicine/Medscape; 2020: https://emedicine.medscape.com/.
Garnick MB (ed.). Harvard Medical School 2015 Annual Report on Prostate Diseases. 2015.
Mir MC, Stephenson AJ . Expectant management of localized prostate cancer. Nargund VH, Raghavan D, Sandler HM (eds.). Urological Oncology. Springer; 2015: 41: 719-730.
PDQ® Adult Treatment Editorial Board. Prostate Cancer Treatment (PDQ®)–Patient Version. Bethesda, MD: National Cancer Institute; 2020: https://www.cancer.gov/.
PDQ® Adult Treatment Editorial Board. Prostate Cancer Treatment (PDQ®)–Health Professional Version. Bethesda, MD: National Cancer Institute; 2020: https://www.cancer.gov/.
National Comprehensive Cancer Network . NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer (Version 3.2020) . 2020 .
Princess Margaret Cancer Centre. Princess Margaret Cancer Centre Clinical Practice Guidelines: Prostate Cancer. 2015: http://www.uhn.ca/.
Zelefsky MJ, Morris MJ, Eastham JA. Cancer of the prostate. DeVita VT Jr., Lawrence TS, Rosenberg SA, eds.. DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 11th ed. Philadelphia, PA: Wolters Kluwer; 2019: 70: 1087-1136.
Parker C, Castro E, Fizazi K et al . Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up . Annals of Oncology . 2020 : 31(9): 1119-1134 .
Raghavan D, Chai Seungjean C, Mahoney J . Castrate resistant prostate cancer: Systemic chemotherapy and a system problem. Nargund VH, Raghavan D, Sandler HM (eds.). Urological Oncology. Springer; 2015: 49: 835-845.
Saad F, Chi KN, Finelli A, Hotte SJ, Izawa J, Kapoor A, et al . The 2015 CUA-CUOG Guidelines for the management of castration-resistant prostate cancer (CRPC) . Canadian Urological Association Journal . 2015 .
Saad F, Aprikian A, Finelli A, et al . 2019 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC) . Canadian Urological Association Journal . 2019 : 13(10):307-14 .
So AI, Chi KN, Danielson B, et al . Canadian Urological Association-Canadian Urologic Oncology Group guideline on metastatic castration-naive and castration-sensitive prostate cancer . Canadian Urological Association Journal . 2020 : 14(2): 17–23 .
James ND, Sydes MR, Clarke NW, et al . Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. Elsevier; 2016: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4800035/pdf/main.pdf.
Sweeney CJ, Chen YH, Carducci M, et al . Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. New England Journal of Medicine. 2015: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562797/pdf/nihms719565.pdf.